WANJIA GROUP HOLDINGS LIMITED 萬嘉集團控股有限公司 ( 於開曼群島註冊成立的有限公司 ) (股份代號：401) 各位註冊股東： 於本公司網站刊登公司通訊之通知 謹此通知 閣下，萬嘉集團控股有限公司（「本公司」）之下述公司通訊（「本次公司通訊」）之英文及中文版本， 現已於本公司網站 www.wanjia-gp.com 及香港聯合交易所有限公司（「聯交所」）網站 www.hkexnews.hk 登載；或 本次公司通訊之印刷本已按 閣下所選擇之語言版本隨件附上（如適用）： 請於本公司網站內的「投資者關係」以閱覽公司通訊。公司通訊亦已載於「披露易」網站www.hkexnews.hk。 倘 閣下因任何原因於瀏覽本公司網站登載的本次公司通訊時出現任何困難，本公司在接獲 閣下要求時，將立 即免費發送所選定的語言版本的本次公司通訊的印刷本予 閣下。請於附奉之變更申請表格（「變更申請表格」） （變更申請表格下方附有已預付郵費的郵寄標籤）甲部適當空格內劃上「✓」號。倘 閣下欲更改本公司所有日後 公司通訊（「公司通訊」）之收取方式及╱或語言版本之選擇，請於附奉之變更申請表格乙部適當空格內劃上「✓」 號 ...

截至月份: 2025年12月31日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 萬嘉集團控股有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00401 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.05 | HKD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.05 | HKD | | 50,000,000 | 本月底法定 ...

Group 1 - The company proposes to increase its authorized share capital from HKD 50 million (split into 1 billion shares) to HKD 100 million (split into 2 billion shares) by adding an additional 1 billion unissued shares, subject to approval at a special general meeting [1] - Following the increase in authorized share capital, the company plans to conduct a rights issue at a subscription price of HKD 0.08 per share, offering 1 share for every share held as of the record date, aiming to issue between 560 million and 641 million shares to raise at least approximately HKD 44.82 million before expenses [1] Group 2 - The estimated net proceeds from the rights issue will be at least approximately HKD 40.82 million and not exceeding approximately HKD 47.28 million, depending on the exercise of outstanding share options [2] - The company intends to use the net proceeds for several purposes, including: (i) developing existing pharmaceutical wholesale and distribution business, as well as dialysis treatment and consulting services, and potential investments in the healthcare sector; (ii) settling trade and other payables of approximately HKD 5 million and repaying a director's loan and accrued interest of approximately HKD 8.5 million; (iii) general working capital, including salaries, rent, professional fees, and other corporate expenses [2]

Group 1 - The company proposes to increase its authorized share capital from HKD 50 million (split into 1 billion shares) to HKD 100 million (split into 2 billion shares) by issuing an additional 1 billion unissued shares, subject to approval at a special shareholders' meeting [1] - Following the increase in authorized share capital, the company plans to conduct a rights issue at a subscription price of HKD 0.08 per share, offering 560 million to 641 million shares to raise at least approximately HKD 44.82 million before expenses [1] - The estimated net proceeds from the rights issue will be at least approximately HKD 40.82 million, assuming no changes in the number of shares issued prior to the record date [2] Group 2 - The company intends to use the net proceeds from the rights issue for several purposes, including the development of existing pharmaceutical wholesale and distribution businesses, as well as dialysis treatment and consulting services [2] - Part of the proceeds will be allocated to settle trade and other payables of approximately HKD 5 million and to repay a director's loan and accrued interest of approximately HKD 8.5 million [2] - The remaining funds will be utilized for general working capital, which includes but is not limited to salaries, rent expenses, professional fees, and other corporate expenses [2]

Group 1 - The company, Wan Jia Group (00401.HK), announced a proposal to increase its authorized share capital from HKD 50 million (1 billion shares) to HKD 100 million (2 billion shares) by adding an additional 1 billion unissued shares [1] - Following the approval of the increase in authorized share capital at a special general meeting, the company plans to conduct a rights issue at a subscription price of HKD 0.08 per share, offering between 560,222,136 and 641,015,190 shares to raise at least approximately HKD 44.82 million and up to approximately HKD 51.28 million before expenses [1] - The estimated net proceeds from the rights issue are expected to be not less than approximately HKD 40.82 million and not more than approximately HKD 47.28 million, depending on the exercise of outstanding share options [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 本公佈僅供參考，並不構成收購、購買或認購本公司證券之邀請或要約。 （於開曼群島註冊成立之有限公司） WANJIA GROUP HOLDINGS LIMITED 萬嘉集團控股有限公 司 （股份代號：401) (I)建議增加法定股本； (II)建議按於記錄日期每持有一(1)股股份獲發 一(1)股供股股份之基準進行供股； 及 (III)補償安排項下之配售協議 本公司財務顧問 衍丰企業融資有限公司 配售代理 京基證券集團有限公司 獨立董事委員會及獨立股東之獨立財務顧問 八方金融有限公司 1 建議增加法定股本 董事會建議於股東特別大會上向股東尋求以普通決議案方式批准透過增設 額外1,000,000,000股未發行股份，將本公司之法定股本由50,000,000港元（分 拆為1,000,000,000股股份）增加至100,000,000港元（分拆為2,000,000,000股股 份）。 建議供股 於增加法定股本生效及 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 萬嘉集團控股有限公司 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00401 | | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 560,222,136 | | 0 | | 560,222,136 | | 增加 / 減少 (-) | | | | | | | | | | 本月底結存 | | | | 560,222,136 | | 0 | | 560,222,136 | 第 2 頁 共 10 頁 v 1.1.1 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 ...

Financial Performance - Revenue for the period was approximately HKD 85,706,000, an increase of about 2.40% compared to HKD 83,695,000 in the same period last year[5] - The company reported a loss attributable to owners of approximately HKD 712,000, compared to a profit of HKD 1,256,000 in the previous year[5] - Basic and diluted loss per share was approximately HKD 0.127, compared to a profit of HKD 0.22 per share in the previous year[7] - Gross profit for the period was HKD 25,774,000, down from HKD 26,433,000 in the previous year[6] - The company reported a total comprehensive income of HKD 152,000, significantly lower than HKD 2,791,000 in the previous year[6] - Total comprehensive income for the period ended September 30, 2025, was HKD 289,000, a significant decrease from HKD 2,726,000 in the previous period[17] - The group recorded a loss attributable to the owners of approximately HKD 712,000, compared to a profit of HKD 1,256,000 in the previous year[61] Cash Flow and Liquidity - Total cash and cash equivalents as of September 30, 2025, were approximately HKD 18,918,000, down from HKD 24,083,000 as of March 31, 2025[5] - As of September 30, 2025, the net cash generated from operating activities was HKD 3,126,000, compared to HKD 11,159,000 for the same period in 2024, representing a decrease of approximately 72%[17] - The net cash used in financing activities was HKD 8,444,000 for the six months ended September 30, 2025, compared to a net cash inflow of HKD 1,630,000 in 2024[17] - The cash and cash equivalents decreased by HKD 5,317,000 during the six months ended September 30, 2025, compared to an increase of HKD 12,815,000 in the same period of 2024[17] Assets and Liabilities - Total assets amounted to HKD 108,159,000 as of September 30, 2025, compared to HKD 106,822,000 as of March 31, 2025[8] - Current liabilities increased to HKD 30,599,000 from HKD 29,002,000 in the previous period[9] - Non-current assets decreased to HKD 48,082,000 from HKD 50,208,000[8] - Total liabilities as of September 30, 2025, were HKD 39,374,000, with HKD 33,404,000 classified liabilities and HKD 5,970,000 unallocated corporate liabilities[30] Revenue Breakdown - Revenue from external customers for the six months ended September 30, 2025, was HKD 85,706,000, with HKD 25,617,000 from pharmaceutical wholesale and distribution, and HKD 60,089,000 from hemodialysis treatment and consulting services[27] - Revenue from the wholesale business was approximately HKD 25,617,000, a decrease of about 5.93% from HKD 27,232,000 in the previous year, attributed to reduced demand from hospitals and clinics[48][53] - Revenue from the dialysis business was approximately HKD 60,089,000, an increase of about 6.42% from HKD 56,463,000 in the previous year, driven by an increase in the number of patients treated[49][54] Shareholder Information - As of September 30, 2025, Mr. Wang holds a total equity interest of 30.12% in the company, including 156,862,198 shares and 2,500,000 options[77] - Major shareholder 威揚 holds 156,862,198 shares, representing approximately 28.00% of the total issued shares as of September 30, 2025[79] - 泓港財務有限公司, Expert Wealth Investments Limited, and 吳國輝 have released their security interest in the 156,862,198 shares held by 威揚[80] Stock Options and Share Schemes - A total of 80,793,054 stock options have been granted under the 2013 stock option plan, representing approximately 14.42% of the total issued shares[83] - The 2023 stock option plan allows for the issuance of 56,022,213 stock options, which is about 10.00% of the total issued shares[84] - The exercise price for stock options ranges from 0.094 to 0.668 per share, with various exercise periods extending to 2033[83] - The 2023 Share Option Scheme was adopted on September 15, 2023, to attract and retain top talent and provide additional incentives to eligible participants[88] Corporate Governance - The audit committee, consisting of three independent non-executive directors, has reviewed the group's unaudited consolidated results for the period and confirmed compliance with applicable accounting standards[101] - The Compensation Committee was established on September 24, 2013, and includes one executive director and three independent non-executive directors[102] - The main responsibilities of the Nomination and Corporate Governance Committee include reviewing the board's structure and recommending changes, as well as maintaining effective corporate governance and internal control systems[104] Compliance and Risk Management - The company is actively monitoring compliance with external regulatory requirements and assessing their impact on existing operations[67] - Following a recent compliance issue, the company is implementing corrective measures to ensure adherence to applicable laws and regulations[74] - The company has not engaged in any major acquisitions or disposals during the reporting period[71] Employee Information - As of September 30, 2025, the company employed 177 full-time employees, with total employee costs amounting to approximately HKD 14,424,000, an increase from HKD 13,360,000 in 2024[73]

WANJIA GROUP HOLDINGS LIMITED 萬嘉集團控股有限公司 ( 於開曼群島註冊成立的有限公司 ) (股份代號：401) 2025 年 11 月 26 日 致本公司的非登記股東 於本公司網站刊發公司通訊的通知 本公司謹通知 閣下，萬嘉集團控股有限公司 (「本公司」) 之下述公司通訊(「公司通訊」) 的英文本及中文 本，現已登載於本公司網站 www.wanjia-gp.com: • 中期報告2025/2026 請於本公司網站內的「投資者關係」以閱覽公司通訊。公司通訊亦已載於「披露易」網站 www.hkexnews.hk 。 致： 萬嘉集團控股有限公司 （「公司」）（股份代號：401） 卓佳證券登記有限公司轉交 香港夏慤道 16 號 遠東金融中心 17 樓 提示 作為非登記股東，如有意以電子方式收取公司通訊1的發佈通知 ， 閣下應聯絡 閣下持有股份的銀行、經紀、託管商、代理人或香 港中央結算（代理人）有限公司（統稱「中介公司」），並向 閣下的中介公司提供 閣下的電子郵件地址。 倘 閣下擬收取公司通訊的印刷本，可填妥隨附之申請表格及利用郵寄標籤寄回本公司之香港股份過戶登記分 處 – 卓佳證券登記 ...

承董事會命 萬嘉集團控股有限公司 行政總裁及執行董事 王佳駿 WANJIA GROUP HOLDINGS LIMITED 萬嘉集團控股有限公司 ( 於開曼群島註冊成立的有限公司 ) (股份代號：401) 各位註冊股東： 於本公司網站刊登公司通訊之通知 謹此通知 閣下，萬嘉集團控股有限公司（「本公司」）之下述公司通訊（「本次公司通訊」）之英文及中文版本， 現已於本公司網站 www.wanjia-gp.com 及香港聯合交易所有限公司（「聯交所」）網站 www.hkexnews.hk 登載；或 本次公司通訊之印刷本已按 閣下所選擇之語言版本隨件附上（如適用）： • 中期報告2025/2026 請於本公司網站內的「投資者關係」以閱覽公司通訊。公司通訊亦已載於「披露易」網站www.hkexnews.hk。 倘 閣下因任何原因於瀏覽本公司網站登載的本次公司通訊時出現任何困難，本公司在接獲 閣下要求時，將立 即免費發送所選定的語言版本的本次公司通訊的印刷本予 閣下。請於附奉之變更申請表格（「變更申請表格」） （變更申請表格下方附有已預付郵費的郵寄標籤）甲部適當空格內劃上「✓」號。倘 閣下欲更改本公司所有日後 公司通訊（「 ...